Klein R G, Arnaud S B, Gallagher J C, Deluca H F, Riggs B L
J Clin Invest. 1977 Jul;60(1):253-9. doi: 10.1172/JCI108762.
Pharmacologic doses of corticosteroids impair intestinal calcium absorption and contribute to negative calcium balance. However, the relationship between the impaired calcium absorption and a possible defect in the conversion of vitamin D to its physiologically active form, 1,25-dihydroxyvitamin D, is unknown. We compared fractional calcium absorption (double-isotope method, 100-mg carrier) and serum 25-hydroxyvitamin D (25-OH-D) (Haddad method) in 27 patients receiving pharmacologic doses of prednisone with 27 age-, sex-, and season-matched normal subjects. In patients receiving high daily doses of prednisone (15-100 mg/day), calcium absorption (P < 0.02) and serum 25-OH-D (P < 0.001) were decreased. However, in patients receiving low doses (8-10 mg/day) or high doses (30-100 mg) of prednisone on an alternate-day schedule, both of these parameters were normal. Calcium absorption in the patients treated with daily prednisone correlated inversely with the dose of corticosteroids (r = -0.52, P < 0.025) and, in all steroid-treated patients, correlated directly with serum 25-OH-D (r = 0.58, P < 0.01). In four patients who received high-dose corticosteroid therapy for an average of 4 wk, serum 25-OH-D decreased by 35.5% from pretreatment values. Administration of a physiologic or near-physiologic dose of synthetic 1,25-dihydroxyvitamin D(3) (0.4 mug daily for 7 days) to patients receiving high-dose corticosteroids led to an increase in calcium absorption in all patients. These results suggest that calcium malabsorption in the corticosteroid-treated patients is due to a dose-related abnormality of vitamin D metabolism and not to a direct effect of corticosteroids on depressing transmucosal intestinal absorption of calcium.
药理剂量的皮质类固醇会损害肠道对钙的吸收,并导致负钙平衡。然而,钙吸收受损与维生素D转化为其生理活性形式1,25-二羟基维生素D的可能缺陷之间的关系尚不清楚。我们比较了27名接受药理剂量泼尼松治疗的患者与27名年龄、性别和季节匹配的正常受试者的钙吸收分数(双同位素法,载体100毫克)和血清25-羟基维生素D(25-OH-D)(哈达德法)。接受高剂量泼尼松每日剂量(15 - 100毫克/天)的患者,其钙吸收(P < 0.02)和血清25-OH-D(P < 0.001)均降低。然而,接受低剂量(8 - 10毫克/天)或高剂量(30 - 100毫克)泼尼松隔日给药方案的患者,这两个参数均正常。每日接受泼尼松治疗的患者的钙吸收与皮质类固醇剂量呈负相关(r = -0.52,P < 0.025),并且在所有接受类固醇治疗的患者中,与血清25-OH-D呈正相关(r = 0.58,P < 0.01)。在4名平均接受高剂量皮质类固醇治疗4周的患者中,血清25-OH-D较治疗前值下降了35.5%。给接受高剂量皮质类固醇治疗的患者给予生理或接近生理剂量的合成1,25-二羟基维生素D(3)(每日0.4微克,共7天),导致所有患者的钙吸收增加。这些结果表明,皮质类固醇治疗患者的钙吸收不良是由于维生素D代谢的剂量相关异常,而非皮质类固醇对抑制钙经肠黏膜吸收的直接作用。